

404A8
404A8(hIL15)
404A8(D8SQ108S
404A8(Q108S)
OD 450nm
ANTIBODY CONCENTRATION (nM)
404E4
404E4(hIL15)
404E4(D8SQ108S)
404E4(Q108S)
OD 450nm
ANTIBODY CONCENTRATION (nM)
146B7
146B7 (hIL-15)
146B7 (D8SQ 108S)
146B7 (Q108S)
OD 450nm
ANTIBODY CONCENTRATION (nM)
146H5
146H5(hIL15)
146H5(D8SQ108S)
146H5(Q108S)
OD 450nm
ANTIBODY CONCENTRATION (nM)

FIG. 1



146B7 VK
AB63
E V Q L V Q S G A E V K K P G E S L K I>
FR1
S C K V S G Y F F T T Y W I G W V R Q M>
CDR1
P G K G L E Y M G I I Y P G D S D T R Y>
CDR2
FR2
S P S F Q G Q V T I S A D K S I S T A Y>
FR3
L Q W S S L K A S D T A M Y Y C A R G G>
N W N C F D Y W G Q G T L V T V S S A S>
CDR3
JH4b
Cγ1
FR4
T K G P S V F P L A>
AB90

FIG. 2




FIG. 3



volunteer 1
146B7
no inhibitor
0.1 ug/ml B7
1 ug/ml B7
10 ug/ml B7
TNF-a (pg/ml)
150
100
50
0
—
50 ng/ml IL-15
100 ng/ml IL-15

FIG. 4A



volunteer 1
isotype control
no inhibitor
0.1 ug/ml T1
1 ug/ml T1
10 ug/ml T1
TNF-a (pg/ml)
150
100
50
0
—
50 ng/ml IL-15
100 ng/ml IL-15

FIG. 4B



volunteer 2
146B7
no inhibitor
0.1 ug/ml B7
1 ug/ml B7
10 ug/ml B7
TNF-a (pg/ml)
150
100
50
0
—
50 ng/ml IL-15
100 ng/ml IL-15

FIG. 4C



volunteer 2
isotype control
no inhibitor
0.1 ug/ml T1
1 ug/ml T1
10 ug/ml T1
TNF-a (pg/ml)
150
100
50
0
—
50 ng/ml IL-15
100 ng/ml IL-15

FIG. 4D



250
200
150
100
50
0
TNF-a (pg/ml)
-
25 ng/ml IL-15
100 ng/ml IL-15
100 ng/ml IL-2
no inhibitor
0.1 ug/ml B7
1 ug/ml B7
10 ug/ml B7

FIG. 5



40000
30000
20000
10000
0
cpm
0.1
1
10
100
antibody concentration (ug/ml)
146B7
146H5
404E4
404A8

FIG. 6



hIL-15
no inhibitor
B7 0.1 ug/ml
B7 1 ug/ml
B7 10 ug/ml
cpm
4000
3000
2000
1000
0
—
25ng/ml
100ng/ml

FIG. 7A



hIL-2
no inhibitor
B7 0.1 ug/ml
B7 1 ug/ml
B7 10 ug/ml
cpm
3000
2000
1000
0
—
10ng/ml
100ng/ml

FIG. 7B



no inhibitor
E4 0.1 ug/ml
E4 1 ug/ml
E4 10 ug/ml
4000
3000
2000
1000
0
cpm
25ng/ml
100ng/ml

FIG. 8A



no inhibitor
E4 0.1 ug/ml
E4 1 ug/ml
E4 10 ug/ml
3000
2000
1000
0
cpm
10ng/ml
100ng/ml

FIG. 8B



no inhibitor
A8 0.1 ug/ml
A8 1 ug/ml
A8 10 ug/ml
4000
3000
2000
1000
0
cpm
25ng/ml
100ng/ml

FIG. 9A



no inhibitor
A8 0.1 ug/ml
A8 1 ug/ml
A8 10 ug/ml
3000
2000
1000
0
cpm
10ng/ml
100ng/ml

FIG. 9B



binding of 146B7 to IFNγ -stimulated monocytes
60
40
20
0
S.I.
PBS
PBS
IFN γ
PBS
IFNγ
0 days
1day
2 days
hIgG-b
146B7-b

FIG. 10



FIG. 11B



FIG. 11A




FIG. 12B




FIG. 12A



SCID/RA xenograft model
nuclei (% area)
15
10
5
0
PBS
146B7
treatment

FIG. 13A




FIG. 13C



FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15A FIG. 15B FIG. 15C




FIG. 16A FIG. 16B FIG. 16C



Binding of 146B7 to IL-15/IL-15Ra complex in ELISA
OD 405 nm
3.0
2.0
1.0
0.0
0.1
1
10
100
unlabeled IL-15 (ng/ml)
Hu IgG1-b 100
Hu IgG1-b 1000
146B7-b 100
146B7-b 1000
blanco

FIG. 17



Binding of 146B7 to IL-15/IL-15Ralpha on Raji cells
S.I.
100
80
60
40
20
0
0
0.32
1.6
8
40
200
1000
unlabeled IL-15 (ng/ml)
hIgG1-100
hIgG1-1000
hIgG1-10000
146B7-100
146B7-1000
146B7-10000

FIG. 18